Current Report Filing (8-k)
February 01 2017 - 4:54PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): January 26, 2017
Proteostasis Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-37695
|
|
20-8436652
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
|
|
200 Technology Square, 4th Floor
Cambridge, MA
|
|
02139
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code (617) 225-0096
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
(b) On January 26, 2017, Proteostasis Therapeutics, Inc.’s Chief Financial
Officer, James DeTore, provided notice of his resignation from the Company, effective February 10, 2017, for personal reasons. The Company has commenced a search for a replacement. Brett Hagen, the Company’s Controller and Principal
Accounting Officer since May 2016, will assume certain of Mr. DeTore’s duties on an interim basis. Prior to joining Proteostasis, Mr. Hagen served as a controller for BIND Therapeutics, Inc. (NASDAQ: BIND), Vice President, Finance/Segment
Controller of Boston Private Financial Holdings (NASDAQ: BPFH), Manager of SEC Financial Reporting and Technical Account of The Princeton Review, Controller of BioProcessors Corporation and held a number of positions at PricewaterhouseCoopers LLP.
He received a B.A. from University of Minnesota, a Master in Accountancy from Wright State University and a M.S. in Finance from Suffolk University.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: February 1, 2017
|
|
|
|
PROTEOSTASIS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jeffrey M. Held
|
|
|
|
|
|
|
|
Jeffrey M. Held
|
|
|
|
|
|
|
|
General Counsel and Secretary
|
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2023 to Apr 2024
